A Phase 1/2 Trial of CV301 in Combination With Anti-PD-1 Therapy Versus Anti-PD-1 Therapy Alone in Subjects With Non-Small Cell Lung Cancer

Trial Profile

A Phase 1/2 Trial of CV301 in Combination With Anti-PD-1 Therapy Versus Anti-PD-1 Therapy Alone in Subjects With Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs CV 301 (Primary) ; Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms MAGNI-lung-01
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 08 Nov 2017 According to a Bavarian Nordic media release, phase II results from this trial are expected in the second half of 2018.
    • 21 Sep 2017 Primary drug has changed from nivolumab to Pembrolizumab,time frame for the assesment of primary end point has also changed from 10 years to 5 years and planned number of patients changed from 160 to 200
    • 21 Sep 2017 Planned number of patients changed from 160 to 200.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top